Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Current Investments (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Cash & Current Investments for 5 consecutive years, with $75.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 28.68% year-over-year to $75.7 million, compared with a TTM value of $75.7 million through Sep 2025, down 28.68%, and an annual FY2024 reading of $112.4 million, changed N/A over the prior year.
  • Cash & Current Investments was $75.7 million for Q3 2025 at Barinthus Biotherapeutics, down from $87.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $243.6 million in Q2 2021 and bottomed at $75.7 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $160.5 million, with a median of $166.7 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments rose 28.64% in 2022, then crashed 33.82% in 2024.
  • Year by year, Cash & Current Investments stood at $214.1 million in 2021, then fell by 9.19% to $194.4 million in 2022, then fell by 17.53% to $160.3 million in 2023, then fell by 29.89% to $112.4 million in 2024, then tumbled by 32.67% to $75.7 million in 2025.
  • Business Quant data shows Cash & Current Investments for BRNS at $75.7 million in Q3 2025, $87.8 million in Q2 2025, and $100.6 million in Q1 2025.